Lete-cel

Overview

Letetresgene autoleucel (“lete-cel”) is an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1. Lete-cel is being investigated for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior anthracycline treatment.

Potential cancer indications in development

Synovial Sarcoma

Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.

Myxoid/Round Cell Liposarcoma (MRCLS)

Soft tissue sarcomas can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues.

Publications

Review our findings and publications.

View Lete-cel Publications View All Publications